ArticlePregnancy (Hoboken, N.J.)2025
Microfluidic device successfully replaces traditional models of pregnancy associated drug pharmacokinetic studies.
Article in Pregnancy (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pregnant and lactating people remain therapeutic orphans as they are often excluded from clinical trials, remaining one of the most therapeutically vulnerable. Current models are not suited to determine pharmacokinetics and dynamics. To mediate this problem, this study evaluated drug propagation using a microphysiologic (MPS) model of the human maternal-fetal interface (FMi-PLA-OOC) with simulation software to see if this could serve as an alternative and more efficient approach to studying pharmacokinetics across the placental barrier during pregnancy surpassing the limitations of traditional placental perfusion systems and animal models. Study design: The humanized FMi-PLA-OOC is composed of seven-cell culture chambers, connected by microchannels containing umbilical vein endothelial cells, placental cytotrophoblasts and syncytiotrophoblasts, chorion trophoblast cells, amnion mesenchymal and epithelial cells, and maternal decidua cells. A physiological dose of indomethacin (15 µg/mL) was introduced into the decidual chamber to assess drug pharmacokinetics. Media and supernatants of the FMi-PLA-OOC were collected at various time points and were analyzed using mass spectrometry to determine the drug concentration. A physiologically based pharmacokinetic (PBPK) pregnancy model was developed using GastroPlus and compared with values from placental perfusion studies, animal models, and clinical data from the literature. Results: Cells in the FMi-PLA-OOC maintained viability, metabolism, and did not show cytotoxicity. The drug propagated and reached the placental layers (umbilical vein cells) in 4 h and the fetal membrane cellular layers (amnion mesenchymal cells) in 1 h. Higher drug concentrations were detected at later time points in the placental cellular layers. Comparing maximum drug concentration ratios in the fetus and mother ( Conclusion: The utilization of the innovative feto-maternal interface MPS model and PBPK simulation yielded data comparable to the current traditional and simulation approaches. Although not tested here, bedsides kinetics, our humanized MPS model can determine other pharmacologic parameters (efficacy, toxicity, metabolism, absorption, and excretion), making preclinical trials easier, cheaper, and faster and in compliance with the FDA Modernization Act 2.0.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.